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Abstract 
Background: There are conflicting results as to the association between pre-existing diabetes and the risk of mortal-
ity in patients with prostate cancer. The purpose of this study is to estimate the influence of pre-existing diabetes on 
prostate cancer-specific mortality and all-cause mortality.
Methods: We searched PubMed and Embase to identify studies that investigated the association between pre-exist-
ing diabetes and risk of death among men with prostate cancer. Pooled risk estimates and 95 % confidence intervals 
were calculated using fixed-effects models or random-effects models. Heterogeneity tests were conducted between 
studies. Publication bias was analyzed by using the Egger’s test, Begg’s test, and the trim and fill method.
Results: Of the 733 articles identified, 17 cohort studies that had 274,677 male patients were included in this meta-
analysis. Pre-existing diabetes was associated with a 29 % increase in prostate cancer-specific mortality [relative risk 
(RR) 1.29, 95 % CI 1.22–1.38, I2 = 66.68 %], and with a 37 % increase in all-cause mortality (RR 1.37, 95 % CI 1.29–1.45, 
p < 0.01, I2 = 90.26 %). Additionally, in a subgroup analysis that was a type specific analysis focusing on type 2 dia-
betes and was conducted only with three cohort studies, pre-existing type 2 diabetes was associated with all-cause 
mortality (RR 2.01, 95 % CI 1.37–2.96, I2 = 95.55 %) and no significant association with prostate cancer-specific mortal-
ity was detected (RR 1.17, 95 % CI 0.96–1.42, I2 = 75.59 %). There was significant heterogeneity between studies and 
no publication bias was found.
Conclusions: This meta-analysis suggests diabetes may result in a worse prognosis for men with prostate cancer. 
Considering heterogeneity between studies, additional studies should be conducted to confirm these findings, and 
to allow generalization regarding the influence that each type of diabetes has on prostate cancer mortality.
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Background
Prostate cancer is the second leading cause of cancer 
death among men in the United States (Siegel et al. 2014). 
In 2015, the American Cancer Society reported that 1 in 
7 men will be diagnosed with prostate cancer during his 
lifetime (Jemal et  al. 2011). The known risk factors for 
prostate cancer include age, ethnicity, and family history 
(Jemal et  al. 2011). Diabetes mellitus influences the risk 
of various cancers, including colon, pancreas, and thyroid 
cancer (Giovannucci et al. 2007; Karlin et al. 2012; Kasper 
et  al. 2009). Prostate cancer appears to be an excep-
tion, whereby a diagnosis of diabetes is associated with 
a reduced incidence in most studies. However, whether 
a previous history of diabetes influences the prognosis 
of prostate cancer is not clear (Batty et  al. 2011; Bensi-
mon et al. 2014; Fleming et al. 2003; Froehner et al. 2003; 
Smith et al. 2008; Yeh et al. 2012).
Diabetes is primarily divided into type 1 and type 2 
diabetes. Recently, the prevalence of type 2 diabetes has 
rapidly escalated owing to the increase in obesity, which 
also increases the risk of various cancers (Baba et  al. 
2011). Although hyperinsulinemia was hypothesized as 
the link between type 2 diabetes and the risk of various 
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cancers (Barone et  al. 2008), the influence of diabetes 
on the risk and prognosis of prostate cancer is complex 
because of the testosterone fluctuations often observed 
among patients with diabetes, and these fluctuations also 
influence the development of prostate tumors (Baradaran 
et al. 2009).
Pre-existing diabetes is defined as having a diagnosis of 
diabetes before the prostate cancer was diagnosed. Some 
prospective cohort studies reported that pre-existing dia-
betes was associated with 32 % increased risk of mortal-
ity among prostate cancer patients (Liu et al. 2012), while 
other studies reported that pre-existing diabetes was not 
associated with the prognosis of prostate cancer (Chiou 
et al. 2012). Since here is a controversy whether pre-exist-
ing diabetes would affect prognosis of prostate cancer, a 
meta-analysis would be necessary. There was two prior 
meta-analyses have studied association between pre-
existing diabetes and prognosis of prostate cancer. These 
two studies indicated that pre-existing diabetes was asso-
ciated with increased risk of prostate cancer death (Cai 
et al. 2015; Snyder et al. 2010). However, the meta-anal-
ysis by Snyder et  al. only included four cohort studies 
(Snyder et  al. 2010), while Cai et  al. included 11 cohort 
studies (Cai et al. 2015). Since these meta-analyses, there 
are six additional cohort studies, which further examine 
the association between pre-existing diabetes and prog-
nosis of prostate cancer. By including more studies, it is 
now possible to further examine subgroup analyses such 
as types of diabetes, level of adiposity and country where 
study was conducted. Therefore, we have included 17 
cohort studies, which met our inclusion criteria to exam-
ine association between pre-existing diabetes and prog-
nosis of prostate cancer.
Methods
Data sources and searches
This meta-analysis study followed the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines. The analysis used the MEDLINE 
and EMBASE databases to identify applicable studies 
that were published between January 1970 and August 
2016. The studies selected for inclusion needed to evalu-
ate the effects of diabetes mellitus on the risk of death in 
patients with prostate cancer and they should have been 
published in the English language and in peer-reviewed 
journals. The search terms used in this study were “dia-
betes mellitus”, “prostate cancer”, “survival”, “prognosis”, 
“death”, and “mortality”. After a study was considered 
relevant on the basis of the search terms, its refer-
ences were manually examined to find additional rel-
evant studies. This study selected articles that reported 
finding in two categories: (1) the association of diabe-
tes with prostate cancer-specific mortality in prostate 
cancer patients, and (2) the association of diabetes with 
all-cause mortality in prostate cancer patients. We then 
separately pooled the results from these two catego-
ries, to determine the relationship between type 2 dia-
betes and both prostate cancer-specific mortality and 
all-cause mortality, exclusively among prostate can-
cer patients. Pre-existing diabetes is defined as having 
a diagnosis of diabetes before the prostate cancer was 
diagnosed.
Eligibility criteria
Two authors (JL and JYJ) independently reviewed the 
articles in a standardized manner. Any disagreements in 
the eligibility for study selection were discussed by all 
three authors (JL, JYJ, and EG) to obtain a consensus. To 
be included in this study, each study had to meet three 
criteria: (1) evaluate prostate cancer, (2) indicate ascer-
tainments of diabetes, including self-report, medication 
use, and blood test, and (3) report the hazard ratio or rel-
ative risk using standard error or a 95 % confidence inter-
val (CI). In cases of publications that were duplicated or 
originated from the same study population, only the most 
recent study with the longest follow-up duration was 
included.
Data extraction and quality assessment
Two authors (JL and JYJ) evaluated the selected arti-
cles by following the guidelines of the Meta-analysis of 
Observational Studies in Epidemiology (MOOSE). In 
case of discrepancies, all three authors (JL, JYJ, and EG) 
conducted further discussions to obtain a consensus. The 
following data elements were extracted for this meta-
analysis study: last name of the first author, publication 
year, country where the study was performed, number 
of deaths, sample size, description of the method used to 
diagnose diabetes, outcome determination, age at base-
line, adjustment factors, follow-up duration, criteria of 
the cause of death, and the relative risk or hazard ratio 
that corresponded to a 95 % CI.
The authors evaluated the quality of the selected stud-
ies using the Newcastle-Ottawa Scale for the following 
factors: clarification as to diabetes status, adjustment for 
intermediate factors (e.g., age, disease stage, and tumor 
differentiation), study endpoints for prostate cancer-
specific mortality and all-cause mortality, duration of 
follow-up, representativeness of the exposed cohort, and 
adequacy of the follow-up of cohorts (Table 1).
Statistical analysis
This meta-analysis study combined the risk estimates 
with CI or SE to estimate prostate cancer-specific mor-
tality and all-cause mortality. The statistical heteroge-
neity between studies was estimated using Q statistic, 
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and inconsistency was quantified using the I2 statistic 
(Borenstein et  al. 2005). Fixed-effect models with forest 
plots were used to pool the results of homogeneous stud-
ies whereas random-effect models with forest plots were 
used for heterogeneous studies.
Publication bias was evaluated using the Egger test 
(Egger et al. 1997) and Begg’s test (Begg and Mazumdar 
1994). To further assess the potential effects of publica-
tion bias, the Duval and Tweedie nonparametric trim 
and fill method was used (Duval and Tweedie 2000). This 
method considers the possibility of hypothetically miss-
ing studies, imputes their RRs, and then recalculates a 
pooled estimate (Borenstein et al. 2010). Statistical signif-
icance was estimated using a p value of <0.05. All statis-
tical analyses were performed using the Comprehensive 
Meta-Analysis software version 1.25 (Biostatic, Inc., 
Englewood, NJ, USA).
Results
Literature search
This meta-analysis study followed the selection processes 
shown in Fig.  1, by using the above-discussed exclu-
sion and inclusion criteria. Of the 733 searched studies 
initially identified, 677 were excluded for the following 
reasons: presented duplicate information, did not report 
prostate cancer-specific mortality or all-cause mortality, 
were reviews or meta-analyses, or did not evaluate diabe-
tes mellitus. An additional 39 studies were excluded from 
this analysis, because they were not mortality studies that 
evaluated diabetes. After applying the selection criteria, 
only 17 studies were included (Table 1). The total num-
ber of patients with prostate cancer was 274,677. The 
follow-up periods ranged between 3 and 17  years. This 
meta-analysis pooled directly the relative risk of prostate 
cancer-specific mortality and all-cause mortality from 
the 17 selected studies and then calculated the overall 
prostate cancer-specific and all-cause mortality, respec-
tively. This study included only prior studies that had 
prospective and retrospective cohort designs, in order to 
understand the association between pre-existing diabetes 
and the prospect of prostate cancer mortality.
Study characteristics
A summary of the descriptive data is presented in Table 1. 
The majority of the studies selected for this meta-analysis 
were conducted in the United States (Best et  al. 2015; 
Chamie et al. 2012; D’Amico et al. 2010; Karlin et al. 2012; 
Merrick et al. 2007; Shetti et al. 2012; Smith et al. 2008; 
Yeh et  al. 2012). The remaining studies were conducted 
in the Republic of Korea (Park et al. 2006), Sweden (Liu 
et al. 2012), Netherlands (van de Poll-Franse et al. 2007), 
United Kingdom (Batty et al. 2011; Bensimon et al. 2014; 
Currie et al. 2012), Italy (Polesel et al. 2016) and Taiwan 
(Chiou et al. 2012; Tseng 2011). All 17 studies were pub-
lished within the last 10 years.
In the studies selected, the prevalence of pre-existing 
diabetes ranged between 18 and 24  %. The average age 
of the participants was 58  years. The methods used for 
Keywords in Medline and 
EMBASE: publication date: 
January 1970– August 2016 
N = 733
Potentially relevant studies 
retrieved 
N = 56 
Studies included in this meta-
analysis   
N = 17 
Studies excluded (N =39)
Not mortality studies    
Studies excluded (N = 677)
Duplicated studies 
Generally ineligible studies or not a 
cohort study 
Did not evaluate diabetes 
Reviews, meta-analyses, or 
guidelines 
Fig. 1 Flow diagram of the process for selecting studies for this meta-analysis
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determining the existence of diabetes were: (1) medical 
records; (2) documented use of diabetes medicine; (3) 
the International Classification of Diseases (ninth revi-
sion) diagnosis codes for surveillance, epidemiology, and 
end results (Medicare); or (4) fasting glucose level. Most 
studies used in the meta-analysis adjusted for age and for 
other factors, including disease stage, alcohol use, smok-
ing history, and physical activity (Table 1).
Association between diabetes and mortality
Seventeen studies examined the association between 
pre-existing diabetes, prostate cancer-specific mortal-
ity, and all-cause mortality in patients with prostate 
cancer (Fig.  2). The association between pre-existing 
diabetes and the risk of prostate cancer-specific mortal-
ity indicated that pre-existing diabetes was significantly 
associated with a 30  % increase in the risk of prostate 
cancer-specific mortality (RR 1.29, 95  % CI 1.22–1.38, 
I2 =  66.68 %, p < 0.01) and with a 65 % increase in the 
risk of all-cause mortality (RR 1.37, 95  % CI 1.29–1.45, 
p  <  0.01, I2 =  90.26  %, p  <  0.01). There was significant 
heterogeneity between studies. There was no evidence of 
publication bias on the basis of analyses using the Egger 
test and Begg’s test. In addition, there was no influence 
of unpublished data in any analysis using the trim and fill 
method.
Association between type 2 diabetes and mortality in a 
subgroup analysis
To further examine whether pre-existing type 2 diabetes, 
separately from type 1 diabetes, was associated with the 
prognosis of prostate cancer, five studies, which evalu-
ated only type 2 diabetes, were included in this ancillary 
analysis (Fig.  3). This analysis showed that pre-existing 
type 2 diabetes was significantly associated with all-cause 
mortality (RR 2.01; 95  % CI, 1.37–2.96, I2  =  75.59  %, 
p  <  0.01) whereas no association was found between 
pre-existing type 2 diabetes and prostate cancer-specific 
mortality. Significant heterogeneity was found between 
studies. In addition, there was no evidence of publication 
bias using the Egger test and Begg’s test and unpublished 
data were not found in any analysis using the trim and fill 
method.
Discussion
This meta-analysis study evaluated the association of pre-
existing diabetes on prostate cancer-specific mortality 
and all-cause mortality. A main finding of this meta-anal-
ysis was that prostate cancer patients with pre-existing 
diabetes had an approximately 29  % higher prostate 
cancer-specific mortality and approximately 37 % higher 
all-cause mortality. In our ancillary analysis, which only 
included results from patients with pre-existing type 2 
diabetes, we found that patients with prostate cancer 
with type 2 diabetes had a doubling in all-cause mortal-
ity. Although we are cautious in asserting that pre-exist-
ing diabetes is a key causal factor for worse prognosis of 
prostate cancer, taking preventative measures towards 
precluding diabetes is appropriate for patients with pros-
tate cancer.
This meta-analysis included 17 studies. Of these, 11 
studies addressed prostate cancer-specific mortality and 
10 addressed all-cause mortality. Two previous meta-
analyses reported the association between pre-existing 
diabetes and prognosis of prostate cancer (Begg and 
Mazumdar 1994; Liu et  al. 2012). The meta-analysis by 
Snyder et al. (2010) of four cohort studies indicated that 
patients with prostate cancer with pre-existing diabetes 
had a 57 % higher all-cause mortality, whereas the meta-
analysis by Cai et  al. (2015) of 11 studies indicated that 
patients with prostate cancer with pre-existing diabe-
tes had a 26 % higher prostate cancer-specific mortality 
and 83 % higher non-prostate cancer mortality. Current 
meta-analysis found six additional studies that have 
reported the impact of pre-existing diabetes on prognosis 
of prostate cancer (Chamie et al. 2012; Chiou et al. 2012; 
Giovannucci and Chan 2010; Karlin et al. 2012; Liu et al. 
2012; Tseng et al. 2012), and the data available in the lit-
erature enabled us to perform an ancillary analysis using 
the studies that evaluated only patients with type 2 dia-
betes. Our analysis showed that type 2 diabetes increased 
the all-cause mortality by approximately 100  % when 
compared to patients with prostate cancer without diabe-
tes. The results from our and other meta-analyses clearly 
showed that pre-existing diabetes, whether type 2 dia-
betes alone or both type 1 and 2 diabetes, increased the 
risk of all-cause mortality in patients with prostate can-
cer. The association between type 2 diabetes and prostate 
cancer mortality was not significant compared to the sig-
nificant association seen for total diabetes mellitus, but it 
might be related to the sub-group analysis between type 
2 diabetes and prostate cancer mortality was conducted 
only with 3 studies. Also, in assessing the observed posi-
tive results from this, there must be an acknowledgement 
that prostate cancer patients with diabetes have been 
found not do well with their diabetes treatment/manage-
ment as well as their anti-cancer treatment/management. 
Unfortunately, our selected studies did not report the 
results after an adjustment for diabetes and cancer treat-
ment/management. A further study that would reflect 
adjustment for this issue could help towards a better 
understanding of the relationship between diabetes and 
cancer treatment/management.
There have been controversies about whether pre-
existing diabetes is associated with the incidence and 
prognosis of prostate cancer (Bensimon et  al. 2014; 
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D’Amico et  al. 2010; Liu et  al. 2012; Tseng 2011). Some 
studies (Batty et al. 2011; Chiou et al. 2012; Smith et al. 
2008) suggested an inverse association, but with very 
wide CI’s. These studies argued that lower androgen lev-
els in patients with type 2 diabetes contributed to the 
better prognosis of prostate cancer. However, other stud-
ies showed significantly worse prognosis in patients with 
prostate cancer with diabetes. It is not clear as to why 
some studies found an inverse association whereas others 
found a direct association between diabetes and progno-
sis of prostate cancer. Our meta-analyses demonstrated 
that pre-existing diabetes is associated with worse prog-
nosis of prostate cancer.
Worse prognosis in patients with prostate cancer with 
diabetes may be related to several mechanisms. First, 
patients with prostate cancer with diabetes are more 
Study name Statistics for each study Odds ratio 
and 95% CIOdds Lower Upper 
ratio limit limit Z-Value p-Value
Park, 2006 1.81
2.41
0.80
1.28
0.24
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4.27
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0.64
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0.61
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0.51
0.54
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0.59
1.23
1.04
1.15
0.22
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5.39
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1.46
7.59
1.87
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-0.98
0.56
-1.38
2.92
2.98
-1.20
7.97
2.39
2.26
-0.82
8.39
0.29
0.02
0.33
0.57
0.17
0.00
0.00
0.23
0.00
0.02
0.02
0.41
0.00
Merrick, 2007
Smitth, 2008
D'Amico, 2010
Batty, 2012
Chamie, 2011a
Chamie, 2011b
Chiou, 2012
Liu, 2012
Bensimon, 2014
Best, 2015
Polesel, 2016
0.10.2 0.5 1 2 5 10
Favours A Favours B
Study name Statistics for each study Odds ratio 
and 95% CIOdds 
ratio
Lower
limit
 Upper 
limit Z-Value p-Value
Van de Poll-Franse, 2007
Smith, 2008
Tseng, 2011 (40-64)
Tseng, 2011 (65-74)
Tseng, 2011(~75)
Batty, 2012
Karlin, 2012
Currie, 2012
Shetti, 2012
Yeh, 2012
Bensimon, 2014
Polesel, 2016
1.19
1.77
6.72
2.76
1.51
0.24
1.36
1.19
1.54
1.43
1.25
1.56
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4.43
2.15
1.08
0.05
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3.55
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6.64
1.40
2.36
1.45
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5.62
8.96
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2.38
-1.81
2.33
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0.46
3.77
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10.96
0.01
0.00
0.00
0.00
0.02
0.07
0.02
0.00
0.01
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0.00
0.04
0.00
0.1 0.2 0.5 1 2 5 10
Favours AFavours B
Prostate cancer-specific mortality: type 2 diabetes vs. non-type 2 diabetes 
All-cause mortality: type 2 diabetes vs. non-type 2 diabetes 
Test for heterogeneity:  
(Q = 112.97, P = 0.00, I
2
= 90.26%) 
Test for heterogeneity:  
(Q = 33.01, P = 0.00, I
2
= 66.68%) 
Fig. 2 Relative risk for the association between pre-existing diabetes, prostate cancer-specific mortality, and all-cause mortality
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likely to have progressive prostate cancer due to the 
adverse interaction between diabetes mellitus and pros-
tate cancer (Lubik et  al. 2011; Ma et  al. 2008). Patients 
with diabetes present with hyperglycemia, and these 
factors are associated with tumor development and 
progression (de Beer and Liebenberg 2014; Lai et  al. 
2014; Venkateswaran et  al. 2007). Second, diabetes can 
diminish the effects of radiotherapy on prostate cancer. 
Accordingly, patients with prostate cancer with diabe-
tes are more likely to experience a higher failure rate of 
radiotherapy treatment and worse gastrointestinal and 
genitourinary complications compared to patients with 
prostate cancer without diabetes (Chan et al. 2005; Her-
old et al. 1999). These complications can be explained by 
possible alterations in insulin-like growth factor 1, which 
may decrease the effectiveness of the treatments (Casa 
et al. 2008). Third, changes in certain hormones, includ-
ing testosterone, sex hormone-binding globulin, and lep-
tin, may affect the risk of prostate cancer (Baradaran et al. 
2009). Additionally, previous studies (Basaria et al. 2006; 
Smith et al. 2006) indicated that low levels of androgens 
in patients with prostate cancer with diabetes contrib-
uted to insulin resistance as well as the risk of prostate 
cancer death and of non-prostate cancer death. In this 
respect, long-term androgen deprivation therapy, which 
is commonly used to treat patients with prostate cancer, 
increases insulin resistance and hyperglycemia, which in 
turn induces cardiovascular diseases (Basaria et al. 2006; 
Smith et al. 2006).
There are several limitations of this study. First, the 
duration of diabetes in the selected studies was not con-
sistent. The duration of diabetes is crucial because recent 
findings indicate that longer durations of diabetes were 
associated with a higher risk of prostate cancer mortality 
and all-cause mortality (Bensimon et  al. 2014). Second, 
the selected studies used different adjustment factors, 
such as tumor stage, treatment methods, and varying 
durations of diabetes, and these different adjustment fac-
tors may influence the RRs found in this study. Third, this 
meta-analysis study did not have adjustment for immor-
tal time bias. This meta-analysis study was unable to 
address this issue as the prospective studies contained 
Study name Statistics for each study Odds ratio 
and 95% CI
0.10.2 0.5 1 2 5 10
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Test for heterogeneity:  
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Test for heterogeneity:  
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Fig. 3 Relative risk for the association between pre-existing type 2 diabetes, prostate cancer-specific mortality, and all-cause mortality
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no information regarding follow up status for those men 
free of diabetes till time of diabetes diagnosis, and then 
till prostate cancer death occurred. Finally, the selected 
studies in this meta-analysis did not provide the Gleason 
scoring content, and therefore, we cannot rule out the 
possibility that only the high grade tumors are positively 
associated with diabetes, while the majority of prostate 
cancer tumors with low histologic grading may not be 
associated with diabetes co-morbidity.
This study suggested that pre-existing diabetes is 
clearly associated with total mortality and possibly pros-
tate cancer-specific mortality in men diagnosed with 
prostate cancer. Future studies are necessary to select 
adequate treatments for patients with prostate cancer 
with diabetes in order to improve prognosis and reduce 
complications. In addition, these studies should examine 
the differences between type 1 and type 2 diabetes and 
determine how factors such as the duration of diabetes, 
radiotherapy treatments, and tumor stages can affect 
prostate cancer mortality.
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